Research interests include clinical and translational research in new drug development, gastrointestinal and genito-urinary malignancies. Dr. Knox is also the Principal Investigator of trials in biliary, hepatocellular, esophageal and renal cell cancers.
Jennifer J Knox
Cell Immunol. 2017 Jul 11;:
J Gastrointest Oncol. 2017 Apr;8(2):352-360
Oncotarget. 2017 03 03;:
Adjuvant sunitinib following chemoradiotherapy and surgery for locally advanced esophageal cancer: a phase II trial.
Dis Esophagus. 2016 Nov;29(8):1152-1158
JCI Insight. 2017 Apr 20;2(8):
Cancer Med. 2017 Apr 16;:
Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials.
BMC Cancer. 2017 Apr 12;17(1):262
Final overall survival analysis for the phase II RECORD-3 Study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.
Ann Oncol. 2017 Feb 21;:
Stereotactic body radiotherapy versus TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis.
J Hepatol. 2017 Feb 28;:
Radiother Oncol. 2017 Feb 12;:
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Associate Professor, Department of Medicine, University of Toronto
Chair, Kidney Disease Oriented Group, National Cancer Institute of Canada
Chair, Hepatobiliary Disease Oriented Group, National Cancer Institute of Canada